121 related articles for article (PubMed ID: 2876498)
1. Acute and long-term effects of SMS 201-995 in acromegaly.
Lamberts SW; del Pozo E
Scand J Gastroenterol Suppl; 1986; 119():141-8. PubMed ID: 2876498
[TBL] [Abstract][Full Text] [Related]
2. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
5. Long-term management of acromegaly with sandostatin.
Tolis G
Horm Res; 1988; 29(2-3):112-4. PubMed ID: 2900189
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
7. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
8. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
Lamberts SW; Uitterlinden P; Verschoor L; van Dongen KJ; del Pozo E
N Engl J Med; 1985 Dec; 313(25):1576-80. PubMed ID: 2866445
[TBL] [Abstract][Full Text] [Related]
10. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).
Sandler LM; Burrin JM; Williams G; Joplin GF; Carr DH; Bloom SR
Clin Endocrinol (Oxf); 1987 Jan; 26(1):85-95. PubMed ID: 2879656
[TBL] [Abstract][Full Text] [Related]
11. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
Barnard LB; Grantham WG; Lamberton P; O'Dorisio TM; Jackson IM
Ann Intern Med; 1986 Dec; 105(6):856-61. PubMed ID: 2877605
[TBL] [Abstract][Full Text] [Related]
12. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
13. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
[TBL] [Abstract][Full Text] [Related]
14. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
[TBL] [Abstract][Full Text] [Related]
15. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analog treatment of acromegaly: new aspects.
Lamberts SW; del Pozo E
Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
[TBL] [Abstract][Full Text] [Related]
17. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
Lamberts SW; Oosterom R; Neufeld M; del Pozo E
J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
[TBL] [Abstract][Full Text] [Related]
18. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K
Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093
[TBL] [Abstract][Full Text] [Related]
19. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations.
Spinas GA; Zapf J; Landolt AM; Stuckmann G; Froesch ER
Acta Endocrinol (Copenh); 1987 Feb; 114(2):249-56. PubMed ID: 2881419
[TBL] [Abstract][Full Text] [Related]
20. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]